How to buy Biodesix stock (Biodesix)

Biodesix is a diagnostics & research business based in the US. Biodesix shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.48 – a decrease of 5.73% over the previous week. Biodesix employs 217 staff and has a trailing 12-month revenue of around $65.6 million.

Our top picks for where to buy Biodesix Inc stock

Buy Biodesix stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biodesix stock price (NASDAQ: BDSX)

Use our graph to track the performance of BDSX stocks over time.

Biodesix shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.48
52-week range	$1.11 - $2.21
50-day moving average more info button	$1.43
200-day moving average more info button	$1.53
Wall St. target price	$3.10
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.37

Is it a good time to buy Biodesix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biodesix price performance over time

Historical closes compared with the close of $1.46 from 2024-12-26

1 week (2024-12-19)	7.35%
1 month (2024-11-27)	2.46%
3 months (2024-09-27)	-14.62%
6 months (2024-06-27)	-2.67%

1 year (2023-12-27)	-19.78%
2 years (2022-12-27)	-14.12%
3 years (2021-12-27)	4.38
5 years (2019-12-24)	N/A

Biodesix financials

Revenue TTM	$65.6 million
Gross profit TTM	$24.1 million
Return on assets TTM	-22.79%
Return on equity TTM	-331.82%
Profit margin	-66.84%
Book value	$0.19
Market Capitalization more info button	$212.4 million

TTM: trailing 12 months

Biodesix share dividends

We're not expecting Biodesix to pay a dividend over the next 12 months.

You may also wish to consider:

Biodesix share price volatility

Over the last 12 months, Biodesix's shares have ranged in value from as little as $1.11 up to $2.21. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biodesix's is 1.213. This would suggest that Biodesix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Biodesix's beta into context you can compare it against those of similar companies.

• Biocept (BIOC.US): 0.595
• Veracyte (VCYT.US): 1.668
• Biogen (BIIB.US): -0.061

Biodesix overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc. , provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.

Frequently asked questions

null
What percentage of Biodesix is owned by insiders or institutions?
Currently 48.618% of Biodesix shares are held by insiders and 42.829% by institutions. How many people work for Biodesix?
Latest data suggests 217 work at Biodesix. When does the fiscal year end for Biodesix?
Biodesix's fiscal year ends in December. Where is Biodesix based?
Biodesix's address is: 919 West Dillon Road, Louisville, CO, United States, 80027 What is Biodesix's ISIN number?
Biodesix's international securities identification number is: US09075X1081